Thoracic Malignancies: A Review of the Latest Evidence
Great therapeutic strides have been made for non-small cell lung cancer (NSCLC). In this conference, renowned specialists from Fox Chase Cancer Center, Temple Lung Center, Johns Hopkins Medicine, Yale Medicine, MedStar Georgetown University Hospital, Jefferson Health, and Penn Medicine presented innovative treatment modalities that include medical, surgical and radiation oncology, pulmonology, and radiologic options.
The conference explored new care paradigms for early-stage disease, including the CheckMate-816 trial that combines immunotherapy with chemotherapy, and a discussion of eligibility through molecular and PD-L1 testing. Targeted therapies for EGFR mutations or ALK translocations, and EGFR-targeted therapy for locally advanced disease, were also be discussed.
Videos from the October 5, 2024 program can be viewed below.
